U.S. Markets closed

Coloplast A/S (COLO-B.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
985.20+14.60 (+1.50%)
At close: 4:59PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close970.60
Open985.60
Bid985.20 x 0
Ask985.40 x 0
Day's Range980.20 - 997.80
52 Week Range855.20 - 1,148.50
Volume284,025
Avg. Volume257,505
Market Cap209.777B
Beta (5Y Monthly)0.11
PE Ratio (TTM)49.56
EPS (TTM)19.88
Earnings DateN/A
Forward Dividend & Yield18.00 (1.77%)
Ex-Dividend DateDec 04, 2020
1y Target Est622.82
  • ACCESSWIRE

    Coloplast A/S to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Coloplast A/S (OTC PINK:CLPBF) will be discussing their earnings results in their 2021 Second Quarter Earnings call to be held on May 6, 2021 at 3:00 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.

  • Coloplast delivers 2% organic growth in Q2 as well as an EBIT margin of 33% and raises full-year underlying EBIT margin guidance from 31-32% to 32-33%
    GlobeNewswire

    Coloplast delivers 2% organic growth in Q2 as well as an EBIT margin of 33% and raises full-year underlying EBIT margin guidance from 31-32% to 32-33%

    Organic growth in Q2 was adversely impacted by the COVID-19 pandemic as well as DKK 150 million in stock building in primarily Europe in Q2 last year. EBIT increased by 2% to 1,577m corresponding to an EBIT margin of 33% before special items. The company maintains full-year organic growth guidance at 7-8% and raises expectations for the EBIT margin from 31-32% to 32-33% before special items. The company reported 2% organic growth in Q2. Reported revenue in DKK was down by 1% to DKK 4,753 million, impacted by the depreciation of the USD and a number of Emerging markets currencies against DKK. The EBIT margin was 33% before special items against 32% last year, which reflects continued strong cost control during the COVID-19 pandemic as well as sustained investments in growth opportunities and innovation. EBIT was impacted by a further DKK 200m provision for costs related to the existing lawsuits in the US alleging injury resulting from the use of transvaginal surgical mesh products. In the first six months of the financial year, organic growth was 4% and the EBIT margin was 33% before special items. “COVID-19 continues to impact our business, but we are encouraged by the vaccination roll-out and remain committed to our priorities: We want to keep our employees safe, while continuing to serve our customers, who rely on our products and services to manage their conditions. I am proud of our teams. They have managed the pandemic with determination and discipline, says CEO Kristian Villumsen and continues. “I would like to highlight our solid Q2 performance in Emerging Markets, led by China, and our strong momentum in Wound Care, driven by Europe and China as well as our newly launched Biatain® Fiber portfolio. Our Interventional Urology business delivered another quarter of growth driven by the Men’s Health portfolio in the US, which continues to lead the recovery as elective procedures resume.”“As expected, our Chronic Care business was negatively impacted by COVID-19 in Q2, due to lower growth in new patients in Europe and a tough comparison period in Q2 of last year, where we saw significant stock building in Europe in the early days of the pandemic. As we head into the second half of this financial year, we expect that growth will pick up, as elective procedures and hospital activity resume in line with the vaccine roll-out.” Organic growth rates by business area in Q2 were 4% in Ostomy Care, 0% in Continence Care, 3% in Interventional Urology, and 1% in Wound & Skin Care. Wound Care in isolation delivered 9% organic growth driven by Europe and China. The recently launched Biatain® Fiber portfolio continued to contribute to growth, especially in Germany and France. Looking at organic growth rates by geography in Q2, the European markets reported -2% growth, Other developed markets contributed with 5% growth, while Emerging markets grew 14%. GPO contract win in the USIn March 2021, Coloplast was awarded a contract for ostomy products with Vizient Inc., the largest healthcare performance improvement company in the US. The contract is effective as of July 1, 2021 and building on the company’s Premier GPO contract win in 2020, Coloplast will now invest in a sales force expansion to support the increased access to hospitals across the US. Key breakthrough in Coloplast’s Sustainability strategyIn Hungary, Coloplast has found a way to recycle the company’s production waste into materials used to build playgrounds and sports fields. Consequently, the company now recycles 58% of its production waste, exceeding the 2025 ambition of 50%. A new ambition will be set and announced in connection with the company’s full-year results. Coloplast continues to invest in innovation and growthColoplast continues to move forward with its new corporate strategy “Strive25 – Sustainable Growth Leadership” and the company plans to annually invest up to 2% of revenue in incremental innovation and commercial initiatives to drive growth. So far this financial year, the company has invested in innovation, sales and marketing activities in Asia, consumer and digital initiatives and Interventional Urology. 2020/21 organic growth guidance unchanged, EBIT margin guidance raised Coloplast continues to expect organic revenue growth of 7-8% at constant exchange rates. Reported growth in DKK is still expected to be 4-5%. The EBIT margin guidance before special items is raised from 31-32% to 32-33% due to efficiency gains and lower costs as a result of COVID-19. After special items, the reported EBIT margin is expected to be 31-32%. This is due to DKK 200m provision costs related to the existing lawsuits in the US alleging injury resulting from the use of transvaginal surgical mesh products. The increased provision is driven by further legal advisory costs as the process is taking longer than anticipated. The company has now settled around 97% of all known cases. Capital expenditure is still expected to be around DKK 1.1 billion. The effective tax rate is still expected to be around 23%. The company will pay a half-year interim dividend of DKK 5.00 per share for a dividend pay-out of DKK 1,065m. CONTACTSPeter MønsterSenior Media Relations Manager, Corporate Communications+45 49 11 26 23dkpete@coloplast.com Ellen BjurgertVice President, Investor Relations+45 49 11 33 76dkebj@coloplast.com Financial highlights and key ratios DKKm2020/21 – Q22019/20 – Q2ChangeRevenue4,7534,823-1%EBIT before special items1,5771,5422%EBIT margin before special items33%32%1%-ptsEBIT margin after special items29%32%-3%-ptsSpecial items*-2000nmNet profit1,1301,0676% *DKK 200m as further provision to cover potential settlements and costs related to the existing lawsuits in the US alleging injury resulting from the use of transvaginal surgical mesh products. Sales performance by business area DKKm2020/21 – Q22019/20 – Q2Organic growthReported growthOstomy Care1,9361,9204%1%Continence Care1,7191,7760%-3%Interventional Urology4955073%-2%Wound & Skin Care6036201%-3%Net revenue4,7534,8232%-1% Sales performance by region DKKm2020/21 – Q22019/20 – Q2Organic growthReported growthEuropean markets2,7682,847-2%-3%Other developed markets1,1431,1725%-2%Emerging markets84280414%5%Net revenue4,7534,8232%-1% Financial highlights for the first 6 months of 2020/2021 DKKm2020/21 – 6mths2019/20 – 6mthsOrganic growthRevenue9,4919,5354%EBIT before special items3,1133,0143%EBIT margin before special items33%32%1%-ptsEBIT margin after special items31%32%-1%-ptsSpecial items*-2000nmNet profit2,2662,1595% Financial guidance for 2020/21 Financial guidance Guidance for 2020/21Guidance for 2020/21 (DKK)Sales growth7-8% (organic)4-5%EBIT margin before special items-32-33% from previously 31-32%EBIT margin after special items-31-32%Capital expenditure-~1.1 billionTax rate-~23%  Attachment 2020_2021_Q2_PM_ENG

  • Coloplast A/S - Announcement no. 03/2021 – Interim Financial Report, H1 2020/21
    GlobeNewswire

    Coloplast A/S - Announcement no. 03/2021 – Interim Financial Report, H1 2020/21

    H1 2020/21Interim financial results, H1 2020/21(1 October 2020 - 31 March 2021) Organic growth guidance maintained at 7-8% and EBIT margin guidance before special items raised from 31-32% to 32-33%. Coloplast delivered 2% organic growth in Q2. Reported revenue in DKK was down by 1% to DKK 4,753 million. Year to date organic growth was 4% and reported revenue in DKK was flat at DKK 9,491 million due to significant FX headwinds.Organic growth rates by business area year to date: Ostomy Care 5%, Continence Care 3%, Interventional Urology 4% and Wound & Skin Care 1%.The Chronic Care business in Q2 was negatively impacted by around DKK 150 million in stock building in the comparison period and lower growth in new patients in Europe due to COVID-19, in particular in the UK.Ostomy Care delivered 4% organic growth in Q2 lifted by solid broad-based performance in Emerging markets. Continence Care delivered flat organic growth in Q2 reflecting lower growth in new patients in Europe and the US.The Interventional Urology business delivered 3% organic growth in Q2. The growth was driven by the Men’s Health portfolio in the US, which continues to lead the recovery as elective procedures resume.The Wound and Skin Care business delivered 1% organic growth in Q2. Wound Care alone delivered 9% organic growth in Q2 driven by Europe and China. The Biatain® Fiber portfolio continued to contribute to growth, especially in Germany and France. Skin Care and in particular Contract manufacturing detracted from growth as a result of COVID-19.EBIT before special items amounted to DKK 3,113 million for H1 20/21, a 3% increase, and an EBIT margin before special items of 33% against 32% last year. EBIT was impacted by a further DKK 200 million provision for costs related to the existing lawsuits in the US alleging injury resulting from the use of transvaginal surgical mesh products.ROIC after tax before special items was 43% for the first six months against 46% in the same period last year negatively impacted by the acquisition of Nine Continents Medical in November 2020.Coloplast has achieved a breakthrough in Hungary around waste recycling. As a result, 58% of the production waste is now recycled (41% in FY 2019/20), exceeding the 2025 target of 50%.Coloplast was awarded a contract for ostomy products with Vizient, Inc., the largest healthcare performance improvement company in the US effective as of July 1, 2021.The Board of Directors has resolved that Coloplast will pay a half-year interim dividend of DKK 5.00 per share for a dividend pay-out of DKK 1,065 million. 2020/21 organic growth guidance unchanged, EBIT margin guidance raised We continue to expect organic revenue growth of 7-8% at constant exchange rates. Reported growth in DKK is still expected to be 4-5%.We now expect a reported EBIT margin before special items of 32-33% from previously 31-32% due to efficiency gains and lower costs as a result of COVID-19. After special items of DKK 200m the reported EBIT margin is expected to be 31-32%.Capital expenditure is still expected to be around DKK 1.1 billion. The effective tax rate is still expected to be around 23%.  Conference call Coloplast will host a conference call on Thursday, 6 May 2021 at 15.00 CEST. The call is expected to last about one hour.To actively participate in the Q&A session please call +45 3544 5577, +44 3333 000 804 or +1 631 913 1422. The participant PIN code is 62535223#.Access the conference call webcast directly here: https://getvisualtv.net/stream/?coloplast-xu5g2qb8j5 For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Ellen BjurgertVice President, Investor RelationsTel. +45 4911 1800 /+45 4911 3376Email: dkebj@coloplast.com Aleksandra DimovskaSr. Manager, Investor RelationsTel. +45 4911 1800 /+45 4911 2458Email: dkadim@coloplast.com Press and mediaPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@coloplast.com AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenmarkCompany reg. (CVR) no. 69749917 Websitewww.coloplast.com This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail. Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees. The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-05.All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 03_2021_H1_202021_Earnings_Release